BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 18024053)

  • 1. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Ernst EJ; Hollanbaugh JL; Miller JG; Pfaller MA; Diekema DJ
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):273-7. PubMed ID: 18024053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to positive culture and identification for Candida blood stream infections.
    Fernandez J; Erstad BL; Petty W; Nix DE
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):402-7. PubMed ID: 19446982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata.
    Blot S; Vandewoude K; Hoste E; Poelaert J; Colardyn F
    J Hosp Infect; 2001 Apr; 47(4):308-13. PubMed ID: 11289775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
    Wilson AG; Micek ST; Ritchie DJ
    Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida glabrata fungaemia in intensive care units.
    Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
    Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
    Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007.
    Nace HL; Horn D; Neofytos D
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):289-94. PubMed ID: 19376670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
    Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
    Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.
    Buckler BS; Sams RN; Goei VL; Krishnan KR; Bemis MJ; Parker DP; Murray DL
    Pediatr Infect Dis J; 2008 Aug; 27(8):762-4. PubMed ID: 18664989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida glabrata fungemia: experience in a tertiary care center.
    Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
    Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
    Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
    Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001].
    Mujica MT; Finquelievich JL; Jewtuchowicz V; Iovannitti CA
    Rev Argent Microbiol; 2004; 36(3):107-12. PubMed ID: 15559191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
    Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
    Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictors of outcome in immunocompetent patients with hematogenous candidiasis.
    Safdar A; Bannister TW; Safdar Z
    Int J Infect Dis; 2004 May; 8(3):180-6. PubMed ID: 15109594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
    Shorr AF; Wu C; Kothari S
    J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.
    Wisplinghoff H; Seifert H; Wenzel RP; Edmond MB
    Clin Microbiol Infect; 2006 Feb; 12(2):170-7. PubMed ID: 16441456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
    Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
    Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
    Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
    Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.